Using Photrexa
®
Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution), Photrexa
®
(riboflavin 5'-phosphate ophthalmic solution), and the KXL
®
system, the iLink
™
corneal cross-linking
procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive
keratoconus and corneal ectasia following refractive surgery.*
1
GET THERE IN TIME
iLink
™
is the only FDA-approved cross-linking procedure that slows
or halts progressive keratoconus to help you preserve vision.
INDICATIONS
Photrexa
®
Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution) and Photrexa
®
(riboflavin 5'-phosphate ophthalmic solution) are indicated for use with the
KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Corneal collagen cross-linking
should not be performed on pregnant women.
IMPORTANT SAFETY INFORMATION
Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects.
The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect,
eye pain, light sensitivity, reduced visual acuity, and blurred vision.
These are not all of the side effects of the corneal collagen cross-linking treatment. For more information, go to www.livingwithkeratoconus.com to obtain the FDA-approved
product labeling.
You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
*Photrexa
®
Viscous and Photrexa
®
are manufactured for Avedro. The KXL System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.
REFERENCE: 1. Photrexa [package insert] Waltham, MA: Glaukos, Inc. 2016.
MA-01953A
© 2021 Glaukos Corporation. iLink
™
is a trademark of Glaukos Corporation. Glaukos and Photrexa
®
are registered trademarks of Glaukos Corporation.
Now from GLAUKOS
LEARN MORE AT GLAUKOS.COM
